Phase 1b study of miricorilant in patients with presumed metabolic dysfunction-associated steatohepatitis (MASH).
BACKGROUND AND AIMS Miricorilant, an oral nonsteroidal selective glucocorticoid receptor modulator, is being investigated as a therapy that modulates hepatic cortisol activity in patients with metabolic dysfunction-associated steatohepatitis (MASH). This phase 1b study evaluated miricorilant's efficacy and safety. AP...